BMC Cancer

Table 3 Specific gallbladder findings (per Independent Ultrasound Review)

From: The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

	Arm A			Arm B			Arm C
	Motesanib 125 mg QD			Motesanib 75 mg BID			Motesanib 75 mg BID
				2 wk on/1 wk off			5 d on/2 d off
Patient incidence, n (%)	Baseline	Post baseline*	Post treatment^†	Baseline	Post baseline*	Post treatment^†	Baseline	Post baseline*	Post treatment^†
	(n = 23)	(n = 23)	(n = 16)	(n = 11)	(n = 11)	(n = 9)	(n = 11)	(n = 11)	(n = 8)
Gallstones	3 (13)	4 (17)	3 (19)	3 (27)	2 (18)	2 (22)	0 (0)	0 (0)	0 (0)
Sludge	0 (0)	9 (39)	4 (25)	0 (0)	4 (36)	4 (44)	0 (0)	3 (27)	0 (0)
Pericholecystic fluid	0 (0)	1 (4)	0 (0)	1 (9)	1 (9)	0 (0)	0 (0)	0 (0)	0 (0)
Common duct dilation	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

*Data within the table indicate number of patients with at least one incidence of the specific gallbladder findings listed at any point during postbaseline treatment.
^†Data within the table indicate number of patients who had the specific gallbladder findings listed at their last available off-treatment assessment.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com